Visudyne Injection

Introduction

Visudyne is a prescription medication that contains the active ingredient Verteporfin. It is commonly known by its brand name Visudyne. This medication is primarily used in the treatment of certain eye conditions, specifically age-related macular degeneration (AMD) and pathologic myopia (severe nearsightedness).

Uses

Visudyne is prescribed for the management of age-related macular degeneration (AMD) and pathologic myopia. Age-related macular degeneration is a condition that affects the central part of the retina, leading to a loss of sharp vision. Pathologic myopia is a severe form of nearsightedness that can cause vision problems and increase the risk of retinal detachment.

Dosage and Administration

Visudyne is administered by a healthcare professional through a vein (intravenous injection). The dosage and frequency of administration will depend on the specific condition being treated and individual patient factors. Follow your healthcare provider’s instructions regarding dosage and administration.

Mechanism of Action

The active ingredient in Visudyne, Verteporfin, works by selectively accumulating in abnormal blood vessels in the eye. When activated by non-thermal red light, Verteporfin produces reactive oxygen species that can cause damage to these abnormal blood vessels. This helps to selectively destroy the abnormal blood vessels while minimizing damage to healthy surrounding tissues.

Side Effects

Common side effects may include injection site reactions, such as pain, swelling, or redness. Inform your healthcare provider if you experience any side effects.

Serious side effects are rare but may include allergic reactions, severe vision changes, or signs of an infection. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Visudyne may interact with certain medications, including blood thinners, photosensitizing agents, and certain antibiotics. Inform your healthcare provider about all medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before using Visudyne. Discuss your medical history and any current medications with your healthcare provider. Inform them if you have a history of liver disease, bleeding disorders, or any other medical conditions.

Visudyne is not recommended for use during pregnancy or breastfeeding. Discuss the potential risks and benefits with your healthcare provider.

Storage

Visudyne should be stored in its original packaging at room temperature, away from excessive heat and moisture. Keep it out of the reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Follow all instructions provided by your healthcare provider regarding the administration of Visudyne.
• If you have any questions or concerns about your treatment, do not hesitate to reach out to your healthcare provider.
• Attend all scheduled follow-up appointments to monitor the effectiveness of the medication and any potential side effects.
• Protect your eyes from direct sunlight and bright indoor lights for at least five days after receiving Visudyne, as it may cause increased sensitivity to light.
• Inform your healthcare provider about any new or worsening vision changes.
• Store contact information for your healthcare provider in case of emergencies or questions regarding your treatment.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Verteporfin 15 mg powder for solution for infusion (Health Professionals SmPC) Available at:
• Verteporfin (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• verteporfin solution, reconstituted (recon soln) (RX) [Accessed 8 Jun. 2024] (online) Available at:
• Verteporfin Injection (MedlinePlus) [Accessed 9 Jun. 2024] (online) Available at:
• Barrette AM, Ronk H, Joshi T, Mussa Z, Mehrotra M, Bouras A, Nudelman G, Jesu Raj JG, Bozec D, Lam W, Houldsworth J, Yong R, Zaslavsky E, Hadjipanayis CG, Birtwistle MR, Tsankova NM. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 2022 May 4;24(5):694-707. doi: 10.1093/neuonc/noab244. [Accessed 29 Jun. 2024] Available at: